Off-the-Shelf CAR-T Cells Struggle to Improve Cancer Treatment – Labiotech.eu (blog)
Labiotech.eu (blog) |
Off-the-Shelf CAR–T Cells Struggle to Improve Cancer Treatment
Labiotech.eu (blog) Data presented at ASH 2017 shows that Servier and Pfizer's UCART19, an allogeneic CAR-T therapy originally developed by Cellectis, might struggle to outperform autologous CAR–T cells. CAR–T cell therapy has proved to be effective at treating cancer in … |
